Last reviewed · How we verify
IPI 504 plus Docetaxel
At a glance
| Generic name | IPI 504 plus Docetaxel |
|---|---|
| Also known as | IPI-504, Docetaxel |
| Sponsor | Infinity Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors (PHASE1)
- A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer (PHASE2)
- A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer (PHASE2)
- Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IPI 504 plus Docetaxel CI brief — competitive landscape report
- IPI 504 plus Docetaxel updates RSS · CI watch RSS
- Infinity Pharmaceuticals, Inc. portfolio CI